These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 29381220)

  • 1. Prediction of Individual Serum Infliximab Concentrations in Inflammatory Bowel Disease by a Bayesian Dashboard System.
    Eser A; Primas C; Reinisch S; Vogelsang H; Novacek G; Mould DR; Reinisch W
    J Clin Pharmacol; 2018 Jun; 58(6):790-802. PubMed ID: 29381220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients.
    Dubinsky MC; Phan BL; Singh N; Rabizadeh S; Mould DR
    AAPS J; 2017 Jan; 19(1):215-222. PubMed ID: 27739008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized Dosing of Infliximab in Patients With Inflammatory Bowel Disease Using a Bayesian Approach: A Next Step in Therapeutic Drug Monitoring.
    Desai DC; Dherai AJ; Strik A; Mould DR
    J Clin Pharmacol; 2023 Apr; 63(4):480-489. PubMed ID: 36458468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dashboard-Driven Accelerated Infliximab Induction Dosing Increases Infliximab Durability and Reduces Immunogenicity.
    Dubinsky MC; Mendiolaza ML; Phan BL; Moran HR; Tse SS; Mould DR
    Inflamm Bowel Dis; 2022 Sep; 28(9):1375-1385. PubMed ID: 34978325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approach-an Indian experience.
    Dave MB; Dherai AJ; Desai DC; Mould DR; Ashavaid TF
    Eur J Clin Pharmacol; 2021 Jan; 77(1):55-62. PubMed ID: 32803288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Decision Support Tools: The Evolution of a Revolution.
    Mould DR; D'Haens G; Upton RN
    Clin Pharmacol Ther; 2016 Apr; 99(4):405-18. PubMed ID: 26785109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of population pharmacokinetics to optimize the dosage regimen of infliximab in inflammatory bowel disease patients.
    Gil Candel M; Gascón Cánovas JJ; Gómez Espín R; Nicolás de Prado I; Rentero Redondo L; Urbieta Sanz E; Iniesta Navalón C
    Rev Esp Enferm Dig; 2020 Aug; 112(8):590-597. PubMed ID: 32686429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab Maintenance Dosing in Inflammatory Bowel Disease: an Example for In Silico Assessment of Adaptive Dosing Strategies.
    Wojciechowski J; Upton RN; Mould DR; Wiese MD; Foster DJR
    AAPS J; 2017 Jul; 19(4):1136-1147. PubMed ID: 28444562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation.
    Berends SE; D'Haens GRAM; Schaap T; de Vries A; Rispens T; Bloem K; Mathôt RAA
    Br J Clin Pharmacol; 2019 Jul; 85(7):1544-1551. PubMed ID: 30927375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualized Dosing of Therapeutic Monoclonal Antibodies-a Changing Treatment Paradigm?
    Strik AS; Wang YC; Ruff LE; Yashar W; Messmer BT; Mould DR
    AAPS J; 2018 Sep; 20(6):99. PubMed ID: 30187153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice.
    Buurman DJ; Maurer JM; Keizer RJ; Kosterink JG; Dijkstra G
    Aliment Pharmacol Ther; 2015 Sep; 42(5):529-39. PubMed ID: 26113313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease.
    Brandse JF; Mould D; Smeekes O; Ashruf Y; Kuin S; Strik A; van den Brink GR; DʼHaens GR
    Inflamm Bowel Dis; 2017 Apr; 23(4):650-660. PubMed ID: 28195852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough Concentration.
    Ternant D; Passot C; Aubourg A; Goupille P; Desvignes C; Picon L; Lecomte T; Mulleman D; Paintaud G
    Clin Pharmacokinet; 2018 Sep; 57(9):1173-1184. PubMed ID: 29236229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's Disease.
    Xiong Y; Mizuno T; Colman R; Hyams J; Noe JD; Boyle B; Tsai YT; Dong M; Jackson K; Punt N; Rosen MJ; Denson LA; Vinks AA; Minar P
    Clin Pharmacol Ther; 2021 Jun; 109(6):1639-1647. PubMed ID: 33354765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.
    Papamichael K; Chachu KA; Vajravelu RK; Vaughn BP; Ni J; Osterman MT; Cheifetz AS
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1580-1588.e3. PubMed ID: 28365486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayes-based dosing of infliximab in inflammatory bowel diseases: Short-term efficacy.
    Santacana Juncosa E; Rodríguez-Alonso L; Padullés Zamora A; Guardiola J; Rodríguez-Moranta F; Serra Nilsson K; Bas Minguet J; Morandeira Rego F; Colom Codina H; Padullés Zamora N
    Br J Clin Pharmacol; 2021 Feb; 87(2):494-505. PubMed ID: 32495380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease.
    Malíčková K; Ďuricová D; Bortlík M; Hind'oš M; Machková N; Hrubá V; Lukáš M; Zima T; Lukáš M
    Biologicals; 2016 Jan; 44(1):33-6. PubMed ID: 26603635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of Population Pharmacokinetic Modeling for Individualized Infliximab Dosing Strategies in Crohn Disease.
    Frymoyer A; Hoekman DR; Piester TL; de Meij TG; Hummel TZ; Benninga MA; Kindermann A; Park KT
    J Pediatr Gastroenterol Nutr; 2017 Dec; 65(6):639-645. PubMed ID: 28471911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease.
    Papamichael K; Vajravelu RK; Osterman MT; Cheifetz AS
    Dig Dis Sci; 2018 Mar; 63(3):761-767. PubMed ID: 29340807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease.
    Hemperly A; Vande Casteele N
    Clin Pharmacokinet; 2018 Aug; 57(8):929-942. PubMed ID: 29330783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.